Pasithea Therapeutics -cw26 (KTTAW) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

Biotech Pasithea Therapeutics Corp. (ticker KTTAW) has bought itself more time on Nasdaq. Its stock traded below $1.00 for 30 consecutive business days, putting the company out of compliance with Nasdaq's minimum bid price rule, and its original 180-day grace period expired on August 19, 2026. The very next day, Nasdaq granted a second 180-day extension, giving the company until February 16, 2027 to get back above $1.00. Management says it may consider moves like a reverse stock split, but it's upfront that there's no guarantee of regaining compliance — and if it fails, the stock faces delisting.